Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
Identifieur interne : 000658 ( Main/Exploration ); précédent : 000657; suivant : 000659Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
Auteurs : Shraddha Sapkota [Canada] ; Myrlene Gee ; Jennifer Sabino ; Derek Emery ; Richard CamicioliSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Atrophy (pathology), Brain (pathology), Dilatation, Female, Homocysteine (metabolism), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (pathology).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , metabolism : Homocysteine.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- pathology : Atrophy, Brain, Parkinson Disease.
- Aged, Aged, 80 and over, Dilatation, Female, Humans, Male, Middle Aged.
Abstract
Parkinson's disease (PD) patients are treated with levodopa (L-dopa) to help stabilize their impaired motor abilities; however, L-dopa leads to increased homocysteine (Hcy) levels, which may have a deleterious effect on brain structure and function. The purpose of this study was to examine the impact of increased Hcy concentration on global brain atrophy as determined by magnetic resonance imaging in PD patients and controls. The effect of high Hcy level on ventricular dilatation (percentage of intracranial volume [%ICV]) and total tissue volume (%ICV) was examined at baseline and longitudinally at 36 months. Age, sex, education, and L-dopa duration (in PD patients) were included as covariates. Elevated Hcy levels correlated positively with ventricular dilatation (%ICV) in the whole sample (P = 0.004) and in the PD group (P = 0.008). At baseline, adults with a high Hcy level (>14 μmol/L) had higher ventricular volume (%ICV) than adults with a low Hcy level (≤ 14 μmol/L) in the whole sample (P = 0.006) and in the PD group (P = 0.03), which persisted over 36 months in both the whole sample (P = 0.004) and the PD group (P = 0.03). PD patients with high Hcy concentrations had a greater rate of ventricular enlargement (%ICV) over time compared with those with low Hcy concentration (P = 0.02). Elevated Hcy concentration was associated with increased ventricular dilatation (%ICV) in PD patients. A larger sample with a broader age range and longer follow-up is needed to establish the consequences of high Hcy level, including interactions with genetic and environmental risk factors, in PD.
DOI: 10.1002/mds.25798
PubMed: 24395213
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000617
- to stream PubMed, to step Curation: 000617
- to stream PubMed, to step Checkpoint: 000675
- to stream Ncbi, to step Merge: 003E80
- to stream Ncbi, to step Curation: 003E80
- to stream Ncbi, to step Checkpoint: 003E80
- to stream Main, to step Merge: 000658
- to stream Main, to step Curation: 000658
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.</title><author><name sortKey="Sapkota, Shraddha" sort="Sapkota, Shraddha" uniqKey="Sapkota S" first="Shraddha" last="Sapkota">Shraddha Sapkota</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Neuroscience, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Neuroscience, University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Gee, Myrlene" sort="Gee, Myrlene" uniqKey="Gee M" first="Myrlene" last="Gee">Myrlene Gee</name></author><author><name sortKey="Sabino, Jennifer" sort="Sabino, Jennifer" uniqKey="Sabino J" first="Jennifer" last="Sabino">Jennifer Sabino</name></author><author><name sortKey="Emery, Derek" sort="Emery, Derek" uniqKey="Emery D" first="Derek" last="Emery">Derek Emery</name></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24395213</idno><idno type="pmid">24395213</idno><idno type="doi">10.1002/mds.25798</idno><idno type="wicri:Area/PubMed/Corpus">000617</idno><idno type="wicri:Area/PubMed/Curation">000617</idno><idno type="wicri:Area/PubMed/Checkpoint">000675</idno><idno type="wicri:Area/Ncbi/Merge">003E80</idno><idno type="wicri:Area/Ncbi/Curation">003E80</idno><idno type="wicri:Area/Ncbi/Checkpoint">003E80</idno><idno type="wicri:Area/Main/Merge">000658</idno><idno type="wicri:Area/Main/Curation">000658</idno><idno type="wicri:Area/Main/Exploration">000658</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.</title><author><name sortKey="Sapkota, Shraddha" sort="Sapkota, Shraddha" uniqKey="Sapkota S" first="Shraddha" last="Sapkota">Shraddha Sapkota</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Neuroscience, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Neuroscience, University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Gee, Myrlene" sort="Gee, Myrlene" uniqKey="Gee M" first="Myrlene" last="Gee">Myrlene Gee</name></author><author><name sortKey="Sabino, Jennifer" sort="Sabino, Jennifer" uniqKey="Sabino J" first="Jennifer" last="Sabino">Jennifer Sabino</name></author><author><name sortKey="Emery, Derek" sort="Emery, Derek" uniqKey="Emery D" first="Derek" last="Emery">Derek Emery</name></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Atrophy (pathology)</term><term>Brain (pathology)</term><term>Dilatation</term><term>Female</term><term>Homocysteine (metabolism)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Homocysteine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Atrophy</term><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Dilatation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) patients are treated with levodopa (L-dopa) to help stabilize their impaired motor abilities; however, L-dopa leads to increased homocysteine (Hcy) levels, which may have a deleterious effect on brain structure and function. The purpose of this study was to examine the impact of increased Hcy concentration on global brain atrophy as determined by magnetic resonance imaging in PD patients and controls. The effect of high Hcy level on ventricular dilatation (percentage of intracranial volume [%ICV]) and total tissue volume (%ICV) was examined at baseline and longitudinally at 36 months. Age, sex, education, and L-dopa duration (in PD patients) were included as covariates. Elevated Hcy levels correlated positively with ventricular dilatation (%ICV) in the whole sample (P = 0.004) and in the PD group (P = 0.008). At baseline, adults with a high Hcy level (>14 μmol/L) had higher ventricular volume (%ICV) than adults with a low Hcy level (≤ 14 μmol/L) in the whole sample (P = 0.006) and in the PD group (P = 0.03), which persisted over 36 months in both the whole sample (P = 0.004) and the PD group (P = 0.03). PD patients with high Hcy concentrations had a greater rate of ventricular enlargement (%ICV) over time compared with those with low Hcy concentration (P = 0.02). Elevated Hcy concentration was associated with increased ventricular dilatation (%ICV) in PD patients. A larger sample with a broader age range and longer follow-up is needed to establish the consequences of high Hcy level, including interactions with genetic and environmental risk factors, in PD.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name><name sortKey="Emery, Derek" sort="Emery, Derek" uniqKey="Emery D" first="Derek" last="Emery">Derek Emery</name><name sortKey="Gee, Myrlene" sort="Gee, Myrlene" uniqKey="Gee M" first="Myrlene" last="Gee">Myrlene Gee</name><name sortKey="Sabino, Jennifer" sort="Sabino, Jennifer" uniqKey="Sabino J" first="Jennifer" last="Sabino">Jennifer Sabino</name></noCountry><country name="Canada"><noRegion><name sortKey="Sapkota, Shraddha" sort="Sapkota, Shraddha" uniqKey="Sapkota S" first="Shraddha" last="Sapkota">Shraddha Sapkota</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000658 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000658 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24395213
|texte= Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24395213" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |